The FDA has approved Pfizers new adadliumab biosimilar - Abrilada (adalimumab-afzb), this is the 5th adalimumab biosimilar to be approved (none are commercially available in the USA until 2023). Abrilada is the 25th biosimilar approved in the U.S. https://t.co/Z0tp3D5yOd